Vericel Corporation (VCEL)

Market Cap	1.09B
Revenue (ttm)	155.22M
Net Income (ttm)	-16.45M
Shares Out	47.18M
EPS (ttm)	-0.24
PE Ratio	n/a
Forward PE	185.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	395,796
Open	23.79
Previous Close	23.75
Day's Range	23.12 - 24.64
52-Week Range	22.06 - 52.87
Beta	2.06
Analysts	Buy
Price Target	46.51 (+100.5%)
Earnings Date	Nov 7, 2022

About VCEL

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric pa...

• Industry: Biotechnology
• IPO Date: Feb 4, 1997
• CEO: Dominick Colangelo
• Employees: 281
• Stock Exchange: NASDAQ
• Ticker Symbol: VCEL

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for VCEL stock is "Buy." The 12-month stock price forecast is 46.51, which is an increase of 100.47% from the latest price.

Price Target

$46.51

(100.47% upside)

Analyst Consensus: Buy

Stock Forecasts